EMA product information as a primary source

Where I part company with post #9, and it is a narrow parting.

Reading this EMA product information thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

Taking post #26 at face value and following it one step further.

I have three months of notes on EMA product information and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.

Marking my uncertainty on EMA product information explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.

I keep a log for EMA product information specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.

On post #49 — agreed on the reasoning, with one qualification.

Language versions of the product information are all official and occasionally differ in emphasis. Where a detail matters, reading two is not paranoid.

I would put a moderate confidence on that and no more.

Post #53 describes the usual case. This is about the unusual one.

On EMA product information the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.

Building on post #57 rather than restating it.

Trying to state the EMA product information position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.

Reporting rather than recommending, on EMA product information. What happened is above. Whether it should have is a different question and not one I am qualified to answer.